T Cell News and Research

Latest T Cell News and Research

Proteostasis acquires Harvard University's two novel protein target licenses

Proteostasis Therapeutics announced today that it has acquired two exclusive licenses from Harvard University to technologies for enhancing the activity of a key cellular protein clearance mechanism, the ubiquitin-proteasome pathway.

27 Apr 2011

MAQUET introduces new pediatric oxygenators and reservoirs in the U.S.

MAQUET Cardiovascular today announced the launch of its QUADROX-i Neonatal and Pediatric oxygenators and reservoirs in the United States. Oxygenators are an integral part of a cardiopulmonary bypass system and function as an artificial lung during surgical procedures.

27 Apr 2011

CESAR, Saladax begin patient enrollment in paclitaxel CEPAC-TDM trial for NSCLC

In collaboration with Saladax Biomedical, Inc., the Central European Society for Anticancer Drug Research announced today that enrollment has begun in the CEPAC-TDM trial of paclitaxel therapeutic drug management with subsequent pharmacokinetic-guided dose adjustment in patients being treated for advanced non-small cell lung cancer.

27 Apr 2011

CTNNB1 activation can improve colorectal cancer survival in obese patients

Among obese patients, activation of the protein biomarker CTNNB1 was associated with better colorectal cancer-specific survival and overall survival, whereas post-diagnosis physical activity was associated with better colorectal cancer-specific survival among patients negative for CTNNB1, according to a study in the April 27 issue of JAMA.

27 Apr 2011

ISCO completes first series of hepatocytes preclinical testing

International Stem Cell Corporation announces successful completion of the first series of preclinical testing of hepatocytes derived in the lab from human parthenogenetic stem cells.

27 Apr 2011

Major breakthrough in understanding of amyotrophic lateral sclerosis

Brandeis researchers have made a significant advance in the effort to understand amyotrophic lateral sclerosis by successfully reversing the toxicity of the mutated protein in the familial type of the disease.

27 Apr 2011

Blueberries may help fight obesity

Recently a study out of the Texas Women's University looked at whether blueberries with their high polyphenol content could help in fighting obesity. Blueberries after all have already been cited as having positive health effects on other conditions like cardiovascular disease and metabolic syndrome. The study was conducted in Petri dishes (not live animals) using a blueberry polyphenol extract and tissue cultures from mice.

27 Apr 2011

Study finds gender difference in immune responses to PTSD

Men and women had starkly different immune system responses to chronic post-traumatic stress disorder, with men showing no response and women showing a strong response, in two studies by researchers at the San Francisco VA Medical Center and the University of California, San Francisco.

27 Apr 2011

Heparan sulfate may have a key role in tumor-spurred lymphatic vessel growth

Cancer has a mighty big bag of tricks that it uses to evade the body's natural defense mechanisms and proliferate. Among those tricks is one that allows tumor cells to turn the intricate and extensive system of lymphatic vessels into something of a highway to metastasis. Yet research unveiled this week may aid in the development of therapeutics that will put the brakes on such cancer spread, and the researchers who completed the study say the findings may extend to other lymphatic disorders.

27 Apr 2011

Researchers develop protein-based inhibitor that can treat HPV

Human papillomavirus causes cervical cancer, the second most common cause of cancer death for women, and is a common cause of anogenital and some head and neck cancers.

27 Apr 2011

ISC-4 topical compound may prevent skin cancer lesion formation

While incidents of melanoma continue to increase despite the use of sunscreen and skin screenings, a topical compound called ISC-4 may prevent melanoma lesion formation, according to Penn State College of Medicine researchers.

27 Apr 2011

Tarix begins patient enrollment for TXA127 Phase 1 study in DCBT

Tarix Pharmaceuticals today announced enrollment of the first patient in a Phase 1 clinical study of TXA127, a pharmaceutical grade formulation of a naturally occurring peptide known to stimulate early hematopoietic precursor cells in the bone marrow.

27 Apr 2011

Motor regulatory protein can block human ovarian tumor growth

A motor regulatory protein can block human ovarian tumor growth, leading to eventual cancer cell death and possible new therapies to treat the disease, according to Penn State College of Medicine researchers.

27 Apr 2011

Lilly and Medtronic’s joint venture in Parkinson’s disease therapy

Lilly has already developed a protein called GDNF (glial cell line derived neurotrophic factor) known to preserve the function of neurons and Medtronic will provide a system that carries the medicine to a key area of the brain.

From Medtronic 26 Apr 2011

Millennium submits two VELCADE sNDAs to FDA

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced that it has submitted two supplemental new drug applications (sNDAs) for VELCADE® (bortezomib) for Injection to the U.S. Food and Drug Administration. The first application seeks to add a subcutaneous route of administration for VELCADE. The second application is for the use of VELCADE in combination with rituximab in patients with relapsed follicular non-Hodgkin lymphoma (NHL).

26 Apr 2011

Real-time GPS tracking bracelet for people with cognitive disorders

Adiant Solutions, a leading distributor of GPS safety and tracking solutions, today announced that its S-911 tracking bracelet is generally available and families and caregivers of those with cognitive disorders can now rest easier knowing that their loved ones are wearing the only tracking bracelet that offers true real-time tracking with accuracy up-to-the-second and within several feet 24/7/365.

26 Apr 2011

Some bacteria avoid antibiotic treatments by going 'off the grid' like rogue secret agents

Going "off the grid," like rogue secret agents, some bacteria avoid antibiotic treatments by essentially shutting down and hiding until it's safe to come out again, says Thomas Wood, professor in the Artie McFerrin Department of Chemical Engineering at Texas A&M University.

26 Apr 2011

Experts to present research on vascular biology and disease at ATVB meetings

Nearly 1,200 experts in cardiovascular medicine, vascular biology, endocrinology, hematology and other disciplines are expected to attend the American Heart Association's Arteriosclerosis, Thrombosis and Vascular Biology 2011 Scientific Sessions, April 28-30, in Chicago, Ill.

26 Apr 2011

Caliber opens world's largest plant-made pharmaceutical facility in Bryan

Caliber Biotherapeutics, a fully-integrated biopharmaceutical company, announced the opening of the world's largest plant-made pharmaceutical manufacturing facility in Bryan, Texas, with the capability of producing 10-100 million doses of infectious vaccines per month, and hundreds of thousands of doses of protein biotherapeutics such as monoclonal antibodies.

26 Apr 2011

Colorectal cancer patients with genetic mutation can benefit from new class of drugs

A class of drugs that shows promise in breast and ovarian cancers with BRCA gene mutations could potentially benefit colorectal cancer patients with a different genetic mutation, a new study from the University of Michigan Comprehensive Cancer Center finds.

26 Apr 2011